age1 Venture Fellowship

age1 is a longevity-focused venture capital firm that evolved from The Longevity Fund, founded by Laura Deming. In 2023, Laura Deming and Alex Colville launched age1 with $55 million in funding dedicated to advancing breakthroughs in longevity and aging science. The firm invests in exceptional founders developing therapeutics, tools, and technologies targeting aging and age-related disease, with check sizes ranging from $500,000 to $4 million at the pre-seed and seed stages.

The Venture Fellow position at age1 is a hands-on role where fellows conceptualize, build, and launch biotech companies at the cusp of longevity science. Fellows are responsible for identifying promising and potentially transformational science and devising strategies to quickly and effectively determine its translational viability. The role is embedded within the firm's San Francisco operations and provides deep exposure to longevity biotech investing and company formation.

age1 focuses on investing in exceptional founders developing therapeutics, tools, and technologies targeting aging and age-related diseases. The firm aims to advance breakthroughs in longevity and aging science, providing first-money-in financing to companies at their earliest stages.

Candidates should emphasize their scientific background and interest in longevity science in their applications. Building connections within the longevity biotech community is also important.

Strong scientific background in biology, biotech, or related life sciences. Deep interest in longevity science and aging biology. Prior research experience, particularly in areas relevant to translational biology, is valued.

The application process is open to individuals with a strong scientific background in biology, biotech, or related life sciences. Candidates should have a deep interest in longevity science and aging biology, with prior research experience valued.

Fellows gain hands-on experience in longevity biotech venture investing, company formation, and scientific due diligence. Access to age1's network of longevity researchers, founders, and investors.

The fellowship operates on a rolling basis with ongoing applications.

The Longevity Fund and age1 have backed multiple longevity biotech companies across therapeutics and platform technologies. Specific venture fellow alumni and their outcomes are not publicly disclosed, but the firm's track record of company formation and early-stage investment in longevity has produced a portfolio of companies addressing core challenges in aging biology.